Solara Active Pharma Sciences Ltd
SOLARA NSE
Solara Active Pharma Sciences Ltd
HealthcareNSE: SOLARA BSE: 541540 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,446 Cr
Volatility
Moderate
P/E Ratio
-1,508.5
EBITDA
₹181 Cr
Return on Equity
0.05%
Debt to Equity
0.55
Book Value
₹262.84
52W High
₹712
52W Low
₹422
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Solara Active Pharma Sciences Ltd insights
48 extracted metrics + investor summaries across FY18–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.27% over past five years.
- Company has a low return on equity of -12.0% over last 3 years.
- Promoters have pledged 37.1% of their holding.
Growth Rate
Revenue Growth
5.95% ↗
Net Income Growth
-1582.00% ↘
Cash Flow Change
95.48% ↗
ROE
-100.08% ↘
ROCE
-125.90% ↘
EBITDA Margin (Avg.)
-20.83% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 |
| Expenses | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 |
| Operating Profit | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 |
| OPM % | 5% | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% |
| Other Income | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 |
| Interest | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 |
| Depreciation | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 |
| PBT | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| Tax % | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 |
| EPS in Rs | -4.07 | -3.58 | -57.36 | -53.2 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.41 |
Profit & Loss
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,431 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,240 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 192 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 13% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | 2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 92 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 103 |
| PBT | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | -2 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | — |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | -2 |
| EPS in Rs | — | 17.3 | 32.01 | 46.22 | -12.11 | -4.62 | -118 | 0.15 | -2.05 | -1.55 |
| Div. Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 |
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Investing | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Financing | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | 0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/OP | 92 | 85 | 103 | 49 | -277 | 106 | -113 | 104 | 83 |
Ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 | 117 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 | 170 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 | 146 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 | 140 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 | -23 |
| ROCE % | — | 10% | 12% | 15% | 0% | 2% | -9% | 6% | 5% |
Documents
1
Clarification sought from Solara Active Pharma Sciences Ltd
10 Jun - Exchange has sought clarification from Solara Active Pharma Sciences Ltd on June 10, 2026, with reference to Movement in Volume. 10 Jun - Exchange has sought clarification from Solara Active Pharma Sciences Ltd on June 10, 2026, with reference to Movement in Volume.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10h - Solara Active Pharma Sciences Limited has informed about the Schedule of Investors/Analysts call to be held on Friday, May 15, 2026 at 15.00 IST, to … 10h - Solara Active Pharma Sciences Limited has informed about the Schedule of Investors/Analysts call to be held on Friday, May 15, 2026 at 15.00 IST, to …
3
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015 ('Listing Regulations')
8 May - Board meets May 15, 2026 to approve audited Q4 and FY2026 standalone and consolidated results. 8 May - Board meets May 15, 2026 to approve audited Q4 and FY2026 standalone and consolidated results.
4
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification. 28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification. 28 Apr - US FDA closed Puducherry facility inspection on Apr 24, 2026 with VAI classification.
3
Submission Of Machine Readable Copy Of Financial Results For The Quarter Ended June 30 2026 24 Jul 2026
General_Announcements
Frequently Asked Questions about Solara Active Pharma Sciences Ltd
What does Solara Active Pharma Sciences Ltd do?
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences)...
Where is Solara Active Pharma Sciences Ltd (SOLARA) listed?
Solara Active Pharma Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: SOLARA and BSE: 541540. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Solara Active Pharma Sciences Ltd belong to?
Solara Active Pharma Sciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has a market capitalisation of approximately ₹2446.19 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Solara Active Pharma Sciences Ltd?
The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd is -1508.50. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Solara Active Pharma Sciences Ltd?
Over the past 52 weeks, Solara Active Pharma Sciences Ltd has traded between a low of ₹422 and a high of ₹712. This range helps investors understand the stock's price volatility and recent trading levels.
Does Solara Active Pharma Sciences Ltd pay dividends?
Yes, Solara Active Pharma Sciences Ltd has a dividend yield of 0.58%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has a Return on Equity (ROE) of 0.05%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Solara Active Pharma Sciences Ltd on Tapetide?
On Tapetide, you can view Solara Active Pharma Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1] It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
Website solara.co.in
CEO Mr. Sandeep Shashikantha Rao M.Sc., PGDM
Employees 1,775
Listed 2018-06-27
Face Value ₹ 10
Issued Size 3,61,71,307